Pharmacy TimesADA 2025: Oral Semaglutide Demonstrates Cardiovascular Benefits in SOUL Trial2 days agoBy Kennedy FerruggiaMore
Vascular NewsSTRIDE trial analysis confirms potential impact of semaglutide on quality-of-life metrics for PAD patients with diabetes2 days agoMore
HCPLiveSemaglutide Offers Functional and Vascular Gains in PAD and T2D, with Subodh Verma, MD, PhD13 hours agoBy Subodh VermaMore
PR NewswireOral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes3 days agoMore
WV NewsSemaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes4 days agoMore
Pharmacy TimesADA 2025: Semaglutide Shows Promise in Improving Mobility for Patients With Diabetes and Peripheral Arterial Disease3 days agoBy Kennedy FerruggiaMore
HCPLiveSTRIDE: Semaglutide Reduces Progression of PAD by 54% in Type 2 Diabetes4 days agoBy Patrick CampbellMore
Full coverageFull coverage